All In MedTech

Device Trial Radar · NCT05786625

Bronchoscopic Microwave Ablation of Lung Tissue

Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue

Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Actual

Start

May 4, 2023

Primary completion

Nov 26, 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Creo Medical LimitedNot on our public-company list
Sponsor type
Industry
First posted
Mar 27, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and feasibility of the Creo Medical MicroBlate™ Flex AB1 instrument used with the AB1 electrosurgical system in patients undergoing bronchoscopic microwave ablation of peripheral lung nodules.

Conditions

  • Lung Cancer

Interventions

  • AblationDevice

    Bronchoscopy and microwave ablation of lung nodule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Performance (Efficacy) EndpointTime frame: Up to day 30 patient visit.
  2. Primary Safety EndpointTime frame: Up to 30 days after the ablation procedure.

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Amsterdam University Medical Centres, Location AMC, Meibergdreef 9

    Amsterdam, Netherlands

  • Royal Brompton and Harefield NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.